ArticleMolecular oncology2008
Cancer research in the UK: A policy review of the junior academic clinical faculty.
Article in Molecular oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A transcription factor that promotes proliferation, migration, invasion, and epithelial-mesenchymal transition of ovarian cancer cells and its possible mechanisms.Biomedical engineering online · 2021Article
- Interference of long non-coding RNA HAGLROS inhibits the proliferation and promotes the apoptosis of ovarian cancer cells by targeting miR-26b-5p.Experimental and therapeutic medicine · 2021Article
- The state of academic cancer surgery in the UK.Molecular oncology · 2008Article
- Cancer research in the UK: A policy review of the junior academic clinical faculty.Molecular oncology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite huge sums spent on academic clinical raining worldwide there is surprisingly little research to inform policymakers. This study addresses the junior faculty in the UK's cancer research community through both current Fellows and senior clinicians and policymakers. Funding organisations under the National Cancer Research Institute umbrella currently support 176 junior faculty fellows (studying towards MD [2 year postgraduate research degree] or PhD) with the majority in medical oncology (49%). Craft specialities (surgery and pathology) had a very modest presence in the junior faculty. The cancer research specific junior faculty makes up a major component of all available junior faculty from National Cancer Research Institute (NCRI) partners (ca. 31%) and is supported both by direct funding to Fellows and via junior faculty positions on clinical programme grants. There was almost universal support for the value of the research experience despite only two thirds of the current cohort expressing a desire to continue to the next level (Clinician Scientist grade). Major issues identified were mentorship, supervision time, pay parity and fit with new UK Clinical Research Collaboration / Modernising Medical Careers (UKCRC/MMC) clinician training programme.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.